Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 201… Read more
Liminatus Pharma, Inc. Class A Common Stock (LIMN) - Total Liabilities
Latest total liabilities as of September 2025: $2.99 Million USD
Based on the latest financial reports, Liminatus Pharma, Inc. Class A Common Stock (LIMN) has total liabilities worth $2.99 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Liminatus Pharma, Inc. Class A Common Stock - Total Liabilities Trend (2021–2024)
This chart illustrates how Liminatus Pharma, Inc. Class A Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Liminatus Pharma, Inc. Class A Common Stock Competitors by Total Liabilities
The table below lists competitors of Liminatus Pharma, Inc. Class A Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Enrg Elements Ltd
AU:EEL
|
Australia | AU$120.48K |
|
Barys Resources Limited
AU:BRY
|
Australia | AU$120.48K |
|
Poddar Housing and Development Limited
NSE:PODDARHOUS
|
India | ₹6.38 Billion |
|
ZIMI Ltd
AU:ZMM
|
Australia | AU$528.27K |
|
Nass Valley Gateway Ltd
PINK:NSVGF
|
USA | $16.03 Million |
|
Champion Electric Metals Inc.
OTCQB:CHELF
|
USA | $2.57 Million |
|
LeanLife Health Inc
PINK:LNLHF
|
USA | $1.67 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Liminatus Pharma, Inc. Class A Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Liminatus Pharma, Inc. Class A Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Liminatus Pharma, Inc. Class A Common Stock (2021–2024)
The table below shows the annual total liabilities of Liminatus Pharma, Inc. Class A Common Stock from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $18.70 Million | +23.06% |
| 2023-12-31 | $15.19 Million | +7.05% |
| 2022-12-31 | $14.19 Million | -34.20% |
| 2021-12-31 | $21.57 Million | -- |